The increase in the global incidence of cancer highlights the need to continue advancing in the techniques of diagnosis and nutritional assessment of cancer patients, given the prognostic and therapeutic impact of nutritional status. In this study, sarcopenia was evaluated as an independent predictor of morbidity and mortality. Data from 45 patients diagnosed with esophagogastric or pancreatic cancer were analyzed. Body composition was determined using computed tomography images, and functionality tests were performed. Sarcopenia was present in 22.2% of the patients, while only 31.1% had correct musculature. A reduction in muscle mass or function was observed in 46.7% of the patients. Likewise, the prevalence of myosteatosis reached 60% of the patients. No significant differences were found with regard to the presence of sarcopenia according to BMI classifications, so it is necessary to evaluate the patient with body composition techniques that include the evaluation of the different muscle and fat compartments. In conclusion, a comprehensive intervention is necessary to improve the detection of sarcopenia/myosteatosis and, in the future, to be able to carry out an approach that improves the quality of life and survival rates of patients.
全球癌症发病率的上升凸显了在癌症患者诊断与营养评估技术方面持续进步的必要性，因为营养状况对预后和治疗具有重要影响。本研究将肌肉减少症作为发病率和死亡率的独立预测因子进行评估。研究分析了45例被诊断为食管胃或胰腺癌患者的数据。通过计算机断层扫描图像确定身体成分，并进行功能测试。结果显示，22.2%的患者存在肌肉减少症，而仅有31.1%的患者肌肉组织正常。46.7%的患者观察到肌肉质量或功能下降。同样，肌肉脂肪变性的患病率达到60%。根据BMI分类，肌肉减少症的存在未发现显著差异，因此有必要采用包含不同肌肉和脂肪区域评估的身体成分技术对患者进行全面评估。总之，需要采取综合干预措施以提高肌肉减少症/肌肉脂肪变性的检测能力，并在未来实施能够改善患者生活质量和生存率的治疗方案。
肿瘤(癌症)患者之家